Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
Nat Med
    March 2026

  1. A biomarker of Alzheimer's disease could be a useful diagnostic tool for other amyloidoses.
    Nat Med. 2026 Mar 19. doi: 10.1038/s41591-026-04336.
    >> Share

  2. MUMMERY CJ, Mayorga AJ, Simmons A, Chow TW, et al
    The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.
    Nat Med. 2026 Mar 5. doi: 10.1038/s41591-026-04273.
    >> Share

    February 2026
  3. O'LEARY K
    A tumor-secreted protein alleviates Alzheimer's disease pathology.
    Nat Med. 2026 Feb 20. doi: 10.1038/d41591-026-00010.
    >> Share

  4. PETERSEN KK, Mila-Aloma M, Li Y, Du L, et al
    Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.
    Nat Med. 2026 Feb 19. doi: 10.1038/s41591-026-04206.
    >> Share


  5. Capillary blood sampling for detecting biomarkers of Alzheimer's disease.
    Nat Med. 2026 Feb 11. doi: 10.1038/s41591-026-04216.
    >> Share

  6. HEALEY N
    Blood tests for Alzheimer's disease could reshape research and care.
    Nat Med. 2026 Feb 5. doi: 10.1038/d41591-026-00008.
    >> Share

    January 2026
  7. HUBER H, Montoliu-Gaya L, Brum WS, Vavra J, et al
    A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.
    Nat Med. 2026 Jan 5. doi: 10.1038/s41591-025-04080.
    >> Share

    December 2025
  8. EDISON P, Femminella GD, Ritchie C, Nowell J, et al
    Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.
    Nat Med. 2025 Dec 1. doi: 10.1038/s41591-025-04106.
    >> Share

    November 2025
  9. JANELIDZE S
    A new blood biomarker for Alzheimer's disease.
    Nat Med. 2025 Nov 3. doi: 10.1038/s41591-025-04028.
    >> Share

  10. YAU WW, Kirn DR, Rabin JS, Properzi MJ, et al
    Physical activity as a modifiable risk factor in preclinical Alzheimer's disease.
    Nat Med. 2025 Nov 3. doi: 10.1038/s41591-025-03955.
    >> Share

  11. LIU Y, Gu X, Li Y, Wang F, et al
    Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function.
    Nat Med. 2025;31:3790-3800.
    >> Share

    October 2025

  12. A brief digital cognitive test improves Alzheimer's disease detection.
    Nat Med. 2025 Oct 16. doi: 10.1038/s41591-025-04024.
    >> Share

    September 2025
  13. TIDEMAN P, Karlsson L, Strandberg O, Calling S, et al
    Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers.
    Nat Med. 2025 Sep 15. doi: 10.1038/s41591-025-03965.
    >> Share

  14. ALI M, Erabadda B, Chen Y, Xu Y, et al
    Author Correction: Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.
    Nat Med. 2025 Sep 2. doi: 10.1038/s41591-025-03970.
    >> Share

    August 2025
  15. SHVETCOV A, Johnson ECB, Winchester LM, Walker KA, et al
    APOE epsilon4 carriers share immune-related proteomic changes across neurodegenerative diseases.
    Nat Med. 2025;31:2590-2601.
    >> Share

  16. IMAM F, Saloner R, Vogel JW, Krish V, et al
    The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
    Nat Med. 2025;31:2556-2566.
    >> Share

  17. OH HS, Le Guen Y, Rappoport N, Urey DY, et al
    Plasma proteomics links brain and immune system aging with healthspan and longevity.
    Nat Med. 2025;31:2703-2711.
    >> Share

    July 2025
  18. CHUI DH, Tanahashi H, Ozawa K, Ikeda S, et al
    Editorial Expression of Concern: Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation.
    Nat Med. 2025 Jul 25. doi: 10.1038/s41591-025-03903.
    >> Share

  19. ALI M, Erabadda B, Chen Y, Xu Y, et al
    Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.
    Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03833.
    >> Share

  20. GATES B
    Global collaboration is key to decoding Alzheimer's disease.
    Nat Med. 2025 Jul 15. doi: 10.1038/d41591-022-00044.
    >> Share

  21. COLONNA M, Holtzman DM
    Rethinking TREM2 as a target for Alzheimer's disease after the INVOKE-2 trial failure.
    Nat Med. 2025 Jul 2. doi: 10.1038/s41591-025-03816.
    >> Share

    June 2025
  22. SELKOE DJ
    In Alzheimer's disease, dimers do the damage.
    Nat Med. 2025;31:1727.
    >> Share

    April 2025

  23. Cerebrospinal fluid biomarker predicts dementia onset and progression in Alzheimer's disease.
    Nat Med. 2025 Apr 28. doi: 10.1038/s41591-025-03700.
    >> Share


  24. Microglia drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Apr 22. doi: 10.1038/s41591-025-03677.
    >> Share

  25. O'LEARY K
    Anti-amyloid could help prevent genetic form of Alzheimer's disease.
    Nat Med. 2025 Apr 17. doi: 10.1038/d41591-025-00026.
    >> Share

  26. PALMQVIST S, Warmenhoven N, Anastasi F, Pilotto A, et al
    Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.
    Nat Med. 2025 Apr 9. doi: 10.1038/s41591-025-03622.
    >> Share

  27. ANDRIEU S, Bateman RJ, Bereczki E, Bose N, et al
    Harnessing artificial intelligence to transform Alzheimer's disease research.
    Nat Med. 2025 Apr 1. doi: 10.1038/s41591-025-03632.
    >> Share

    March 2025
  28. HORIE K, Salvado G, Koppisetti RK, Janelidze S, et al
    Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease.
    Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03617.
    >> Share

  29. OH HS, Urey DY, Karlsson L, Zhu Z, et al
    A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease.
    Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03565.
    >> Share

  30. VAN OLST L, Simonton B, Edwards AJ, Forsyth AV, et al
    Author Correction: Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Mar 28. doi: 10.1038/s41591-025-03664.
    >> Share

  31. GRANDE G, Valletta M, Rizzuto D, Xia X, et al
    Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.
    Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03605.
    >> Share

  32. RAJJI TK, Baksh SN, Shade DM, Ismail Z, et al
    Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.
    Nat Med. 2025 Mar 25. doi: 10.1038/s41591-025-03569.
    >> Share

  33. RASH BG, Ramdas KN, Agafonova N, Naioti E, et al
    Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
    Nat Med. 2025 Mar 10. doi: 10.1038/s41591-025-03559.
    >> Share

  34. VAN OLST L, Simonton B, Edwards AJ, Forsyth AV, et al
    Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Mar 6. doi: 10.1038/s41591-025-03574.
    >> Share

  35. MOUTINHO S
    Women twice as likely to develop Alzheimer's disease as men - but scientists do not know why.
    Nat Med. 2025;31:704-707.
    >> Share

  36. DUFF EP, Zetterberg H, Heslegrave A, Dehghan A, et al
    Plasma proteomic evidence for increased beta-amyloid pathology after SARS-CoV-2 infection.
    Nat Med. 2025;31:797-806.
    >> Share

    February 2025
  37. ISLAM T, Hill E, Abrahamson EE, Servaes S, et al
    Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease.
    Nat Med. 2025 Feb 10. doi: 10.1038/s41591-024-03400.
    >> Share

  38. LLIBRE-GUERRA JJ, Fernandez MV, Joseph-Mathurin N, Bian S, et al
    Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.
    Nat Med. 2025 Feb 10. doi: 10.1038/s41591-025-03494.
    >> Share

    December 2024
  39. MOGUILNER S, Baez S, Hernandez H, Migeot J, et al
    Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations.
    Nat Med. 2024;30:3646-3657.
    >> Share

    July 2024
  40. FORTEA J, Vaque-Alcazar L, Pegueroles J, Alcolea D, et al
    Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03159.
    >> Share

  41. PAPPALETTERA C, Carrarini C, Cappa S, Caraglia N, et al
    Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03158.
    >> Share

  42. ROSENZWEIG N, Kleemann KL, Rust T, Carpenter M, et al
    Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.
    Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03122.
    >> Share

    June 2024
  43. JACK CR JR, Andrews SJ, Beach TG, Buracchio T, et al
    Revised criteria for the diagnosis and staging of Alzheimer's disease.
    Nat Med. 2024 Jun 28. doi: 10.1038/s41591-024-02988.
    >> Share

  44. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 Jun 17. doi: 10.1038/s41591-024-03127.
    >> Share

    May 2024
  45. SHANKS HRC, Chen K, Reiman EM, Blennow K, et al
    p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
    Nat Med. 2024 May 17. doi: 10.1038/s41591-024-02977.
    >> Share

  46. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02931.
    >> Share

  47. XU Q, Liang Z, Huang Y
    APOE4 homozygosity is a new genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02923.
    >> Share

    March 2024
  48. O'LEARY K
    A timeline of biomarker changes before Alzheimer's disease.
    Nat Med. 2024 Mar 15. doi: 10.1038/d41591-024-00018.
    >> Share

    February 2024
  49. BARTHELEMY NR, Salvado G, Schindler S, He Y, et al
    Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests.
    Nat Med. 2024 Feb 21. doi: 10.1038/s41591-024-02869.
    >> Share

    January 2024
  50. JUCKER M, Walker LC
    Evidence for iatrogenic transmission of Alzheimer's disease.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02768.
    >> Share

  51. BANERJEE G, Farmer SF, Hyare H, Jaunmuktane Z, et al
    Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02729.
    >> Share

  52. O'LEARY K
    Modeling real-world data to repurpose drugs for Alzheimer's disease.
    Nat Med. 2024 Jan 18. doi: 10.1038/d41591-024-00003.
    >> Share

    December 2023
  53. O'LEARY K
    Positive results in Alzheimer's disease trials.
    Nat Med. 2023;29:2973.
    >> Share

    November 2023
  54. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Author Correction: Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Nov 20. doi: 10.1038/s41591-023-02718.
    >> Share

    October 2023
  55. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Author Correction: Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02639.
    >> Share

    September 2023
  56. LONGO FM, Massa SM
    Senolytic therapy for Alzheimer's disease.
    Nat Med. 2023 Sep 27. doi: 10.1038/s41591-023-02541.
    >> Share

  57. GONZALES MM, Garbarino VR, Kautz TF, Palavicini JP, et al
    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.
    Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02543.
    >> Share

  58. SELF WK, Holtzman DM
    Emerging diagnostics and therapeutics for Alzheimer disease.
    Nat Med. 2023 Sep 4. doi: 10.1038/s41591-023-02505.
    >> Share

    August 2023

  59. Events in the brain during the evolution of Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02477.
    >> Share

  60. JOHNSON ECB, Bian S, Haque RU, Carter EK, et al
    Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02476.
    >> Share


  61. A fluid biomarker accurately detects tau aggregate pathology in Alzheimer's disease.
    Nat Med. 2023 Aug 2. doi: 10.1038/s41591-023-02468.
    >> Share

  62. PALMQVIST S, Rossi M, Hall S, Quadalti C, et al
    Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
    Nat Med. 2023;29:1971-1978.
    >> Share

  63. QUADALTI C, Palmqvist S, Hall S, Rossi M, et al
    Clinical effects of Lewy body pathology in cognitively impaired individuals.
    Nat Med. 2023;29:1964-1970.
    >> Share

    July 2023
  64. O'LEARY K
    Putting the brakes on Alzheimer's disease.
    Nat Med. 2023 Jul 31. doi: 10.1038/d41591-023-00067.
    >> Share

  65. HORIE K, Salvado G, Barthelemy NR, Janelidze S, et al
    CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
    Nat Med. 2023 Jul 13. doi: 10.1038/s41591-023-02443.
    >> Share

  66. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Jul 4. doi: 10.1038/s41591-023-02406.
    >> Share

    June 2023
  67. BOUZID H, Belk JA, Jan M, Qi Y, et al
    Clonal hematopoiesis is associated with protection from Alzheimer's disease.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02397.
    >> Share

    May 2023
  68. BELLAVER B, Povala G, Ferreira PCL, Ferrari-Souza JP, et al
    Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease.
    Nat Med. 2023 May 29. doi: 10.1038/s41591-023-02380.
    >> Share

  69. LJUBENKOV PA, Rabinovici GD
    Silencing tau to treat early Alzheimer's disease.
    Nat Med. 2023 May 17. doi: 10.1038/s41591-023-02357.
    >> Share

  70. LOPERA F, Marino C, Chandrahas AS, O'Hare M, et al
    Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
    Nat Med. 2023 May 15. doi: 10.1038/s41591-023-02318.
    >> Share

    April 2023
  71. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Apr 24. doi: 10.1038/s41591-023-02326.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016